- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00811018
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3)
2012년 3월 29일 업데이트: Pfizer
A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.
연구 개요
상세 설명
Open-label extension
연구 유형
중재적
등록 (실제)
1192
단계
- 3단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Amsterdam, 네덜란드, 1081 HV
- Pfizer Investigational Site
-
-
-
-
-
Berlin, 독일, 14050
- Pfizer Investigational Site
-
Dresden, 독일, 01307
- Pfizer Investigational Site
-
Giessen, 독일, 35392
- Pfizer Investigational Site
-
Greifswald, 독일, 17487
- Pfizer Investigational Site
-
Hannover, 독일, 30625
- Pfizer Investigational Site
-
Heidelberg, 독일, 69120
- Pfizer Investigational Site
-
Leipzig, 독일, 04103
- Pfizer Investigational Site
-
Regensburg, 독일, 93053
- Pfizer Investigational Site
-
-
-
-
CP
-
Monterrey, CP, 멕시코, 64020
- Pfizer Investigational Site
-
-
DF
-
Tlalpan, DF, 멕시코, 14080
- Pfizer Investigational Site
-
-
N.l.
-
Monterrey, N.l., 멕시코, 64360
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, 미국, 35294
- Pfizer Investigational Site
-
-
Arizona
-
Phoenix, Arizona, 미국, 85013
- Pfizer Investigational Site
-
-
California
-
Los Angeles, California, 미국, 90073
- Pfizer Investigational Site
-
San Francisco, California, 미국, 94143-0124
- Pfizer Investigational Site
-
Torrence, California, 미국, 90502
- Pfizer Investigational Site
-
-
Colorado
-
Denver, Colorado, 미국, 80262
- Pfizer Investigational Site
-
Denver, Colorado, 미국, 80218
- Pfizer Investigational Site
-
-
Florida
-
Sarasota, Florida, 미국, 34233
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Pfizer Investigational Site
-
Augusta, Georgia, 미국, 30912
- Pfizer Investigational Site
-
Decatur, Georgia, 미국, 30033
- Pfizer Investigational Site
-
Decatur, Georgia, 미국, 30030
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- Pfizer Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- Pfizer Investigational Site
-
New Orleans, Louisiana, 미국, 70112-1393
- Pfizer Investigational Site
-
-
Maine
-
Portland, Maine, 미국, 04102
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21205
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02118
- Pfizer Investigational Site
-
Boston, Massachusetts, 미국, 02114
- Pfizer Investigational Site
-
Boston, Massachusetts, 미국, 02111
- Pfizer Investigational Site
-
Boston, Massachusetts, 미국, 02218
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109-0570
- Pfizer Investigational Site
-
Detroit, Michigan, 미국, 48201
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- Pfizer Investigational Site
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08903-0019
- Pfizer Investigational Site
-
-
New York
-
New York, New York, 미국, 10032
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- Pfizer Investigational Site
-
Cleveland, Ohio, 미국, 44195
- Pfizer Investigational Site
-
Columbus, Ohio, 미국, 43210
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19140
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, 미국, 15213
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37232-5735
- Pfizer Investigational Site
-
Nashville, Tennessee, 미국, 37232-2650
- Pfizer Investigational Site
-
-
Texas
-
Galveston, Texas, 미국, 77555-0561
- Pfizer Investigational Site
-
Houston, Texas, 미국, 77030
- Pfizer Investigational Site
-
San Antonio, Texas, 미국, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, 미국, 84143
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- Pfizer Investigational Site
-
Milwaukee, Wisconsin, 미국, 53215
- Pfizer Investigational Site
-
-
-
-
-
Bruxelles, 벨기에, 1070
- Pfizer Investigational Site
-
Leuven, 벨기에, B - 3000
- Pfizer Investigational Site
-
-
-
-
-
Sao Paulo, 브라질, 05403-000
- Pfizer Investigational Site
-
-
MG
-
Belo Horizonte, MG, 브라질, 30380-090
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, 브라질, 90035-003
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, 스페인, 08036
- Pfizer Investigational Site
-
-
-
-
-
Capital Federal, 아르헨티나, C1039AAO
- Pfizer Investigational Site
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, 아르헨티나, C1416ASA
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, 영국, G11 6NT
- Pfizer Investigational Site
-
London, 영국, NW3 2QG
- Pfizer Investigational Site
-
Newcastle, 영국, NE7 7DN
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Papworth Everard, Cambridgeshire, 영국, CB3 8RB
- Pfizer Investigational Site
-
-
-
-
-
Graz, 오스트리아, 8036
- Pfizer Investigational Site
-
Wien, 오스트리아, 1090
- Pfizer Investigational Site
-
-
-
-
-
Petach Tikva, 이스라엘, 49100
- Pfizer Investigational Site
-
Tel-Hashomer, Ramat Gan, 이스라엘, 52601
- Pfizer Investigational Site
-
-
-
-
-
Bologna, 이탈리아, 40138
- Pfizer Investigational Site
-
-
-
-
-
Quebec, 캐나다, G1V 4G5
- Pfizer Investigational Site
-
-
Alberta
-
Calgary, Alberta, 캐나다, T1Y 6J4
- Pfizer Investigational Site
-
Edmonton, Alberta, 캐나다, T6G 2B7
- Pfizer Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Pfizer Investigational Site
-
-
Ontario
-
London, Ontario, 캐나다, N6A 4G5
- Pfizer Investigational Site
-
Toronto, Ontario, 캐나다, M5G 2C4
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3T 1E2
- Pfizer Investigational Site
-
-
-
-
-
Krakow, 폴란드, 31-202
- Pfizer Investigational Site
-
Warszawa, 폴란드, 01-138
- Pfizer Investigational Site
-
Zabrze, 폴란드, 41-800
- Pfizer Investigational Site
-
-
-
-
-
Clamart Cedex, 프랑스, 92141
- Pfizer Investigational Site
-
GRENOBLE Cedex 09, 프랑스, 38043
- Pfizer Investigational Site
-
Strasbourg, 프랑스, 67098
- Pfizer Investigational Site
-
-
-
-
-
Chermside, 호주, QLD 4032
- Pfizer Investigational Site
-
-
New South Wales
-
Darlinghurst, New South Wales, 호주, 2010
- Pfizer Investigational Site
-
-
Queensland
-
Chermside Q, Queensland, 호주, 4032
- Pfizer Investigational Site
-
-
Victoria
-
Melbourne, Victoria, 호주, 3004
- Pfizer Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
12년 (어린이, 성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Diagnosis of Pulmonary Arterial Hypertension (PAH) confirmed by cardiac catheterization.
- Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms.
Exclusion Criteria:
- Has portal hypertension or chronic liver disease.
- Has history of left sided heart disease or significant cardiac disease.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Sitaxsentan
|
Sitaxsentan 100 mg tablets once daily
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Day 1 up to 82 months
|
All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported.
|
Day 1 up to 82 months
|
The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN)
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
ALT and AST data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
ALT and AST data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Percentage of Participants With Total Bilirubin > 1.5 x ULN
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Total builirubin data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Percentage of Participants With Laboratory Test Abnormalities (Hematology)
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Hematology data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Percentage of Participants With Laboratory Test Abnormalities (Chemistry)
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Chemistry data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Percentage of Participants With Laboratory Test Abnormalities (Urinalysis)
기간: Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Urinalysis data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months
|
Percentage of Participants With Anticoagulant Use
기간: Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
Participants with anticoagulant use before first dose or participants with anticoagulant use from first dose of sitaxsentan.
|
Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
Percentage of Participants With Elevated International Normalize Ratio (INR)
기간: Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
Elevated INR in participants who took warfarin, warfarin derivatives, other anticoagulant and no anticoagulants.
Elevated INR defined as > 3.5.
Percentage calculated using number of participants with INR data as the denominator.
|
Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
Percentage of Participants With Electrocardiography (ECG) Results of Potential Clinical Importance
기간: Weeks 28,60,72,84,96,104, Transition Visit up to 82 months
|
Standard 12-lead ECG results determined to be of potential clinical importance according to investigator clinical judgement.
|
Weeks 28,60,72,84,96,104, Transition Visit up to 82 months
|
Percentage of Participants With Vital Sign Results of Potential Clinical Importance
기간: Day 1, Weeks 28,60,72,84,96,104, Transition visit, every 6 months Post Transition, up to 82 months
|
Vital signs include sitting blood pressure, respiration rate, heart rate and temperature.
Potential clinical importance determined according to investigator clinical judgement.
|
Day 1, Weeks 28,60,72,84,96,104, Transition visit, every 6 months Post Transition, up to 82 months
|
Percentage of Participants With Abnormal Prothrombin Time (PT)
기간: Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
PT data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
Percentage of Participants With Abnormal Partial Thromboplastin Time (PTT)
기간: Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
PTT data were analyzed by several local laboratories.
There were subtle differences in the reference ranges used for analysis.
|
Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2003년 3월 1일
기본 완료 (실제)
2011년 7월 1일
연구 완료 (실제)
2011년 7월 1일
연구 등록 날짜
최초 제출
2008년 12월 9일
QC 기준을 충족하는 최초 제출
2008년 12월 16일
처음 게시됨 (추정)
2008년 12월 18일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2012년 4월 24일
QC 기준을 충족하는 마지막 업데이트 제출
2012년 3월 29일
마지막으로 확인됨
2011년 11월 1일
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- B1321007
- FPH03
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
폐동맥 고혈압에 대한 임상 시험
-
University Hospital, Strasbourg, France완전한
-
University of Colorado, Denver모병단심실 | 폐 혈관 저항 이상 | 대사체학 | 우수한 Cavo-Pulmonary 문합 | 엔도텔린미국